2021-06-02T07:53:10-05:00 2020-09-30 GRANT THORNTON LLP 757 THIRD AVENUE 3RD FLOOR NEW YORK NY 100172013 990 2019-10-01 135661935 NATIONAL MULTIPLE SCLEROSIS SOCIETY % TAMI CAESAR CFO & COO NATI 2129863240 733 THIRD AVENUE NEW YORK NY 100173211 TAMI CAESAR CFO & COO 2129863240 2021-06-01 true Daniel Romano P00504182 2125990100 2019 2022-09-23 18:48:47Z CYNTHIA ZAGIEBOYLO 733 THIRD AVENUE NEW YORK NY 100173211 265925664 false 1048 X WWW.NATIONALMSSOCIETY.ORG X 1946 NY WE WILL CURE MS WHILE EMPOWERING PEOPLE AFFECTED BY MS TO LIVE THEIR BEST LIVES. 36 35 1136 35000 1190061 0 191054088 150008066 68661 24770 3350822 2859446 2416266 2338232 196889837 155230514 41056076 31812020 0 0 84199757 80367312 3227503 2196878 29825360 52810366 44217459 181293702 158593669 15596135 -3363155 184662971 173433035 66108264 57601368 118554707 115831667 X WE WILL CURE MS WHILE EMPOWERING PEOPLE AFFECTED BY MS TO LIVE THEIR BEST LIVES. false false 44396018 2905302 0 CLIENT AND COMMUNITY SERVICES - THE SOCIETY PROVIDES INFORMATION, RESOURCES, AND SUPPORT THAT SEEKS TO MEET THE NEEDS OF PEOPLE AFFECTED BY MS AS A WHOLE AND INDIVIDUALLY. THE SOCIETY IS COMMITTED TO OFFERING PROGRAMS FOR ALL PEOPLE REGARDLESS OF WHERE THEY LIVE OR WHERE THEY ARE IN THEIR MS JOURNEY. PROGRAMS, SERVICES AND RESOURCES FOR PEOPLE AFFECTED BY MS FACILITATE EDUCATION, RECREATION, PHYSICAL AND EMOTIONAL WELLNESS, PROVIDE FINANCIAL RESOURCES AND A CONNECTION FOR PEOPLE AFFECTED BY MS. MS NAVIGATORS PARTNER WITH INDIVIDUALS TO NAVIGATE THE CHALLENGES OF MS UNIQUE TO EACH SITUATION. THEY PROVIDE: INFORMATION AND EDUCATION; EMOTIONAL SUPPORT RESOURCES; ASSIST WITH THE COMPLEXITIES OF FINDING A HEALTHCARE PROVIDER, BENEFITS, INSURANCE AND ACCESS TO COVERAGE, AND EMPLOYMENT; RESOURCES TO FACE FINANCIAL CHALLENGES AND PLAN FOR THE FUTURE; WELLNESS STRATEGIES THAT CAN MAKE AN IMPACT ON QUALITY OF LIFE WITH MS; ASSESSMENT OF PERSONALIZED CASE MANAGEMENT; AND CRISIS INTERVENTION IN TIMES OF NEED. IN 2020, MS NAVIGATORS PROVIDED SUPPORT TO 41,045 PEOPLE. IN ADDITION, MORE THAN 21,100 PEOPLE PARTICIPATED IN 159 SOCIETY PROGRAMS (IN PERSON, PHONE BASED, AND ONLINE) ON TOPICS SUCH AS: COVID & MS, MS EDUCATION; HEALTH AND WELLNESS; FAMILY AND RELATIONSHIPS; FINANCIAL RESOURCES; MOBILITY AND ACCESSIBILITY; SOCIAL AND EMOTIONAL SUPPORT; AND RESEARCH AND CLINICAL TRIAL UPDATES. COMMUNITY PROGRAMS INCLUDE COLLABORATING WITH OTHER COMMUNITY ORGANIZATIONS, FOCUSING ON ACCESS TO HEALTHCARE, REHABILITATION, TREATMENTS AND THERAPIES; LONG-TERM CARE; DISABILITY RIGHTS ISSUES; VOCATIONAL TRAINING AND REHABILITATION, WELLNESS AND FITNESS; AND, OUTREACH AND EDUCATION TO RURAL AND UNDERSERVED POPULATIONS. 32060082 0 0 PUBLIC EDUCATION - THE SOCIETY SEEKS TO EXPAND AND DEEPEN THE INDIVIDUAL AND COLLECTIVE EXPERIENCES OF THE MS MOVEMENT. THIS INCLUDES EDUCATING THE PUBLIC ABOUT MULTIPLE SCLEROSIS INCLUDING THE SOCIETY'S AWARENESS CAMPAIGNS, PUBLIC SERVICE ANNOUNCEMENTS, MOMENTUM, WHICH IS THE SOCIETY'S FLAGSHIP MAGAZINE DISTRIBUTED QUARTERLY TO 550,000 PEOPLE LIVING WITH MULTIPLE SCLEROSIS, HEALTHCARE PROVIDERS, AND SUPPORTERS OF THE SOCIETY. THE COMMUNICATIONS PLAN INCLUDES OUTREACH ACROSS ONLINE AND OFFLINE CHANNELS AND WEEKLY EMAILS FROM THE CEO. IN ADDITION TO NATIONWIDE EMAIL NEWSLETTERS SHARED TWICE MONTHLY WITH APPROXIMATELY 1.1 MILLION RECIPIENTS , MANY PEOPLE ENGAGED IN CONVERSATIONS VIA THE SOCIETY'S ONLINE COMMUNITY (55,000 ACTIVE MEMBERS), AND SOCIAL MEDIA (OVER 867,000 FOLLOWERS). MORE THAN 450,000 PEOPLE VISIT THE SOCIETY'S WEBSITE EACH MONTH TO ACCESS INFORMATION AND SUPPORT. 31784643 27082679 0 RESEARCH AND SCIENTIFIC STUDIES - IN FISCAL 2020, THE SOCIETY INVESTED $32.1 MILLION TO SUPPORT NEARLY 400 NEW AND ONGOING RESEARCH PROJECTS AROUND THE WORLD AIMED AT STOPPING MS IN ITS TRACKS, RESTORING FUNCTION, AND ENDING THE DISEASE FOREVER. THE SOCIETY ENGAGED 112 EXPERT PEER REVIEWERS TO EVALUATE 566 RESEARCH GRANTS, FELLOWSHIPS AND PILOT GRANT PROPOSALS TO HELP THE SOCIETY IDENTIFY THE MOST PROMISING RESEARCH INVESTMENTS. RESEARCH PRIORITY AREAS TO DRIVE BREAKTHROUGHS TO A CURE INCLUDE: DEFINING THE CONTRIBUTION OF GENETICS AND THE RISK FOR DEVELOPING MS AND DISEASE COURSE; UNDERSTANDING MS PATHOLOGY AND PATHOPHYSIOLOGY; UNDERSTANDING AND TREATING MS PROGRESSION; IDENTIFYING STRATEGIES FOR NEUROPROTECTION AND NERVOUS SYSTEM REPAIR; AND, ELUCIDATING THE CAUSE OF MS SYMPTOMS, THE IMPACT OF COMORBIDITIES, AND IDENTIFYING REHABILITATION, WELLNESS BEHAVIORS AND LIFESTYLE APPROACHES THAT IMPACT DISEASE COURSE, SYMPTOMS AND OVERALL HEALTH. 5849026 1824039 24770 PROFESSIONAL EDUCATION AND TRAINING 5849026 1824039 24770 114089769 true true false true false false false false true true true false false false true true false true false false true true false true true false false true true true false false false false false false false false true false false false true false false false false true 1407 0 true 1136 true true true false false false false true true false false false false false false X 36 35 false false false false true true true true true false true true true true true true true true true true false AL AK AZ AR CA CO CT DE FL GA HI ID IL IN IA KS KY LA ME MD MA MI MN MS MO MT NE NV NH NJ NM NY NC ND OH OK OR PA RI SC SD TN TX UT VT VA WA WV WI WY X X X TAMI CAESAR CFO COO 2124760424 733 THIRD AVENUE NEW YORK NY 100173211 CYNTHIA ZAGIEBOYLO PRESIDENT & CEO 40.0 0.0 X X 570915 0 11200 PAUL WEISS THRU 11220 CHIEF CRM, MKT & TECH OFFICER 40.0 0.0 X 343839 0 42893 TIM COETZEE CHIEF ADVOC, SVC & RSRCH OFFCR 40.0 0.0 X 335983 0 49237 JOHN SCOTT CHIEF DEV & COMM LEAD. OFFICER 40.0 0.0 X 345012 0 27643 TAMI CAESAR CFO & COO 40.0 0.0 X 300378 0 46826 LISA GOLDFARB CHIEF HR & VOL ENG OFFICER 40.0 0.0 X 312801 0 11200 MAUREEN REEDER EVP, LEAD & ORG(THRU 01/25/19) 40.0 0.0 X 290484 0 2430 JENNIFER LEE EVP, FUNDRAISING EVENTS 40.0 0.0 X 257154 0 34213 PHYLLIS ROBSHAM EVP, COMMUNITY LEADERSHIP 40.0 0.0 X 258254 0 24316 ERIC HILTY CHIEF LEGAL OFF.(THRU 11/6/20) 40.0 0.0 X 236833 0 39272 BARI TALENTE EVP, ADVOCACY 40.0 0.0 X 225666 0 46762 KAY JULIAN EVP, SERVICES (THRU 11/02/20) 40.0 0.0 X 241504 0 26050 BRUCE BEBO EVP, RESEARCH PROGRAMS 40.0 0.0 X 209849 0 39878 RON ZWERIN EVP, MARKETING 40.0 0.0 X 212028 0 32247 ELIZABETH CRITES EVP, INDIV GIVING & CORP REL 40.0 0.0 X 208705 0 7754 REBECCA FEHLIG EVP, OPERATIONS 40.0 0.0 X 191466 0 6430 GRAHAM MCREYNOLDS FMR AVP, GLOBAL INITIATIVES 40.0 0.0 X 101308 0 24071 PETER A GALLIGAN CHAIR 5.0 0.0 X X 0 0 0 RICHARD KNUTSON CHAIR ELECT 5.0 0.0 X X 0 0 0 WILLIAM T MONAHAN VICE CHAIR 5.0 0.0 X X 0 0 0 LAURA VACCARO VICE CHAIR 5.0 0.0 X X 0 0 0 CAROLINE WHITACRE VICE CHAIR 5.0 0.0 X X 0 0 0 LINDA MCALEER SECRETARY 5.0 0.0 X X 0 0 0 PETER PORRINO TREASURER 5.0 0.0 X X 0 0 0 MINDY B ALPERT DIRECTOR 5.0 0.0 X 0 0 0 RICK ANDERSON DIRECTOR (Thru 11/20/19) 5.0 0.0 X 0 0 0 GREGORY R BISHOP DIRECTOR 5.0 0.0 X 0 0 0 MICHAEL BOGDONOFF DIRECTOR 5.0 0.0 X 0 0 0 RON BOIRE DIRECTOR (Thru 11/20/19) 5.0 0.0 X 0 0 0 HAFIZ CHANDIWALA DIRECTOR 5.0 0.0 X 0 0 0 DOUG COY DIRECTOR 5.0 0.0 X 0 0 0 KASSAUNDRA ESCALERA DIRECTOR (As of 11/20/19) 5.0 0.0 X 0 0 0 DANA M FOOTE DIRECTOR 5.0 0.0 X 0 0 0 ELIZABETH FORSTNEGER DIRECTOR 5.0 0.0 X 0 0 0 BRENDON GALLAGHER DIRECTOR (As of 11/20/19) 5.0 0.0 X 0 0 0 SHYAM GIDUMAL DIRECTOR 5.0 0.0 X 0 0 0 PETER HARBILAS DIRECTOR 5.0 0.0 X 0 0 0 ANDY HARRIS DIRECTOR 5.0 0.0 X 0 0 0 IAN HARRIS DIRECTOR 5.0 0.0 X 0 0 0 BONNIE HIGGINS DIRECTOR 5.0 0.0 X 0 0 0 WILLIAM HOLLEY DIRECTOR 5.0 0.0 X 0 0 0 MARY HUGHES MD DIRECTOR (Thru 11/20/19) 5.0 0.0 X 0 0 0 WILLIAM MARRACCINI DIRECTOR (Thru 11/20/19) 5.0 0.0 X 0 0 0 EUGENE MAY DIRECTOR 5.0 0.0 X 0 0 0 RICK MCDERMOTT DIRECTOR (As of 11/20/19) 5.0 0.0 X 0 0 0 ELIZABETH PAGE DIRECTOR 5.0 0.0 X 0 0 0 RUSSEL PARKER DIRECTOR 5.0 0.0 X 0 0 0 MIKE PONGON DIRECTOR 5.0 0.0 X 0 0 0 CHET POREMBSKI DIRECTOR 5.0 0.0 X 0 0 0 ELIZABETH RODRIGUEZ DIRECTOR (As of 11/20/19) 5.0 0.0 X 0 0 0 NANETTE REID DIRECTOR (As of 11/20/19) 5.0 0.0 X 0 0 0 TOBI ROGOWSKY DIRECTOR 5.0 0.0 X 0 0 0 DAVID M ROTTKAMP DIRECTOR 5.0 0.0 X 0 0 0 LARRY SCHMID DIRECTOR (Thru 11/20/19) 5.0 0.0 X 0 0 0 RICHARD B SLIFKA DIRECTOR (Thru 11/20/19) 5.0 0.0 X 0 0 0 PETER G TARRICONE DIRECTOR (Thru 11/20/19) 5.0 0.0 X 0 0 0 DIANA TWADELL DIRECTOR 5.0 0.0 X 0 0 0 MALCOLM P WATTMAN ESQ DIRECTOR 5.0 0.0 X 0 0 0 MITZI WILLIAMS DIRECTOR (As of 11/20/19) 5.0 0.0 X 0 0 0 4642179 0 472422 124 true true false Merkle Inc 29432 Network Place CHICAGO IL 60673 Direct Marketing 7854733 blackbaud po box 930256 ATLANTA GA 311930256 fundraising software 2970966 EVENT 360 INC 55 E JACKSON BOULEVARD SUITE 1010 CHICAGO IL 60604 event production 2385446 ROYLE PRINTING 745 S BIRD STREET SUN PRAIRIE WI 53590 PRINTING 871963 promotor line inc 4218 gateway drive suite 140 COLLEYVILLE TX 76034 event production 800012 45 68118410 437120 81452536 2289940 150008066 PROGRAM REGISTRATION FEES 900099 24770 24770 24770 2848479 2848479 0 0 1050600 1050600 0 1050600 1050600 103174172 103163205 10967 10967 10967 7531945 68118410 7531945 0 0 0 0 0 0 ADVERTISING INCOME 900099 1190061 0 1190061 0 MISC. REVENUE 900099 97571 0 0 97571 1287632 155230514 24770 1190061 4007617 26121771 26121771 2905802 2905802 2784447 2784447 0 3186282 2255580 386858 543844 0 59332395 42001607 7203753 10127035 1783988 1262891 216600 304497 10733609 7598359 1303205 1832045 5331038 3773860 647260 909918 35908 35908 38696 38696 155636 155636 334399 334399 2196878 2196878 271772 271772 7479217 5139184 650671 1689362 1862887 436252 48471 1378164 2513315 208540 70555 2234220 6758187 4434009 818476 1505702 0 10003666 6788488 1266464 1948714 1436392 965225 99796 371371 0 2285298 1934014 114087 237197 0 0 1607077 1090562 203456 313059 1147972 779015 145332 223625 PRINTING, PUBLICATION, AND POS 6729451 2196331 779022 3754098 EQUIPMENT RENTAL 543757 368986 68820 105951 DUES 327633 295293 11190 21150 AWARDS AND PRIZES 211151 172245 985 37921 475045 242909 141527 90609 158593669 114089769 14678540 29825360 X 4587221 541671 744149 3301401 0 0 62786233 71802303 11504081 13736856 1779167 1186539 0 0 0 0 0 0 0 0 6333401 5027379 15166212 12940508 3781209 2225704 95165057 75690296 152704 52243 0 0 0 0 3161119 3711715 184662971 173433035 11019663 11680963 31424423 27666761 8175570 4239000 0 0 10030005 7842574 0 0 0 0 0 0 5458603 6172070 66108264 57601368 X 68662718 60336737 49891989 55494930 118554707 115831667 184662971 173433035 X -3363155 368948 271167 X false true X true false X 106277577 175698717 189707218 191054088 150008066 812745666 0 0 106277577 175698717 189707218 191054088 150008066 812745666 8771258 803974408 1020380 2186940 2842090 3845510 3899079 13793999 1605654 2213290 1669341 1468467 1190061 8146813 2908 22954181 22220034 23943974 7629516 76750613 911437091 902899 0.88209 0.88518 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED true true true 5726 true 298849 true 13108 false true 283994 true 277877 false 879554 false LOBBYING ACTIVITIES SCHEDULE C, PART II-B, LINE 1 35,937 MS ACTIVISTS ARE ON THE FRONTLINE, MOVING TOGETHER AND SPEAKING WITH ONE VOICE TO CREATE LEGISLATIVE AND REGULATORY CHANGES THAT BENEFIT PEOPLE LIVING WITH MS AND THEIR FAMILIES. MS ACTIVISM DRIVES CHANGE IN PUBLIC POLICIES TO BRING POSITIVE IMPACT FOR PEOPLE AFFECTED BY MS. ACTIVISTS SHARE STORIES ABOUT LIVING WITH MS, CONNECT WITH DECISION-MAKERS, WORK WITH LIKE-MINDED PARTNERS AND CREATE SYSTEMIC CHANGE TO IMPACT THE GREATEST NUMBER OF PEOPLE POSSIBLE. STATE AND LOCAL ACTIVISM PRIORITIES ARE DETERMINED BY BOTH AN ORGANIZATIONAL PROCESS AND BY ADVOCACY STAFF AND GOVERNMENT RELATIONS VOLUNTEERS. TOP AREAS OF FOCUS FOR MS ACTIVISTS IN 2020 INCLUDED INCREASED FUNDING FOR MS RESEARCH, ENDING SURPRISE MEDICAL BILLING, AND ENSURING PEOPLE WITH MS GOT WHAT THEY NEED IN THE CONGRESSIONAL COVID-19 RELIEF PACKAGES INCLUDING H.R. 6202, THE FAMILIES FIRST CORONAVIRUS RESPONSE ACT, S.3548, THE CORONAVIRUS AID, RELIEF, AND ECONOMIC SECURITY ACT (CARES ACT) AND H.R. 133, THE CONSOLIDATED APPROPRIATIONS ACT OF 2021. false true X 21446141 291990 -870352 193288 393886 20280605 20596603 256566 1007744 219134 195638 21446141 9143474 10413196 1507782 145245 322604 20596603 2464959 5496277 1286554 104316 9143474 2402557 62402 2464959 0.85850 0.14150 false false 0 4117962 3549805 568157 0 4697722 3987206 710516 0 6350528 5403497 947031 2225704 0 OTHER LIABILITIES 2564160 DUE TO ANNUITANTS 1844906 LONG TERM DEFERRED RENT 1763004 6172070 X 160978864 368948 5380007 271167 6020122 154958742 271772 271772 155230514 163701904 5380007 5380007 158321897 271772 271772 158593669 ESCROW LIABILITY ARRANGEMENT EXPLANATION SCHEDULE D, PART IV, LINE 2B THE SOCIETY IS A MANAGING MEMBER, ALONG WITH ASSOCIANZIONE ITALIANA SCLEROSI MULTIPLA (ITALY), MS RESEARCH AUSTRALIA, MULTIPLE SCLEROSIS INTERNATIONAL FEDERATION, MS SOCIETY (UNITED KINGDOM), AND THE MULTIPLE SCLEROSIS SOCIETY OF CANADA. THE ALLIANCE IS OPEN TO MS ORGANIZATIONS FROM AROUND THE WORLD AND IS CONTINUALLY SEEKING NEW MEMBER ORGANIZATIONS FROM THE GLOBAL MS COMMUNITY. THE ALLIANCE MADE A JOINT COMMITMENT TO ACCELERATE THE DEVELOPMENT OF TREATMENT FOR PROGRESSIVE MS. THE ALLIANCE HAS FOUR STRATEGIC OBJECTIVES WHICH INCLUDE: BETTER UNDERSTAND PROGRESSION SO TREATMENTS CAN BE IDENTIFIED AND TESTED, DESIGN SHORTER, FASTER TRAILS THAT MEASURE PATIENT OUTCOMES, CONDUCT TRAILS TO TEST AGENTS, DEVELOP AND EVALUATE NEW THERAPIES TO MANAGE SYMPTOMS. AS A MANAGING MEMBER, THE SOCIETY COMMITTED TO PROVIDING FUNDS OF $7,691,526 THROUGH 2020 AND HAS COMMITTED $12,993,082 OVER THE FOLLOWING FIVE YEARS, CONDITIONAL ON VARIOUS FACTORS. IN ADDITION, THE SOCIETY MAINTAINS CUSTODY OF THE POOLED FUNDS CONTRIBUTED FROM OTHER ALLIANCE MEMBERS. THE DISBURSEMENT OF FUNDS FOR VARIOUS PROGRESSIVE MS RESEARCH INITIATIVES IS APPROVED BY VOTING ALLIANCE MEMBERS. THE SOCIETY RECEIVED A TOTAL OF $1,153,017 DURING THE YEAR ENDING SEPTEMBER 30, 2020 FROM ALLIANCE MEMBERS, WHICH WILL BE HELD UNTIL SUCH TIME THE FUNDS ARE APPROVED FOR EXPENDITURE. AS OF SEPTEMBER 30, 2020, THE SOCIETY RECORDED UNSPENT DONATED FUNDS, CONSISTING OF BOTH SOCIETY AND OTHER ALLIANCE MEMBERS MONIES, TOTALING $7,842,574, AS A LIABILITY. SCHEDULE D, PART V INTENDED USES OF ENDOWMENT FUND THE ENDOWMENT ASSETS ARE INVESTED IN A MANNER INTENDED TO PRESERVE THEIR VALUE CONSISTENT WITH SUCH DONOR STIPULATIONS, MINIMIZE THE EFFECT OF HIGH ECONOMIC VOLATILITY AND/OR LOW INVESTMENT RETURN AND PROVIDE FUNDING FOR THE PROGRAMS SPECIFIED BY THE DONORS. SCHEDULE D, PART V, LINE 1C prior period adjustments CERTAIN AMOUNTS IN THE 2019 SUMMARIZED COMPARATIVE INFORMATION HAVE BEEN RECLASSIFIED TO CONFORM TO THE 2020 PRESENTATION. THE PRIOR YEAR ADJUSTMENTS AS REFLECTED ON SCHEDULE D, PART V, LINE 1C ARE LISTED AS FOLLOWS: NET REALIZED AND UNREALIZED GAIN $1,778,250 PRIOR YEAR ADJUSTMENTS $(2,648,602) --------- NET AMOUNT $(870,352) FIN 48 FOOTNOTE SCHEDULE D, PART X, LINE 2 GUIDANCE IN "ACCOUNTING FOR UNCERTAINTY IN INCOME TAXES" UNDER THE ASC OF THE FASB CLARIFIES THE ACCOUNTING FOR UNCERTAINTY IN TAX PROVISION TAKEN OR EXPECTED TO BE TAKEN IN A TAX RETURN, INCLUDING ISSUES RELATING TO FINANCIAL STATEMENT RECOGNITION AND MEASUREMENT. THIS STANDARD PROVDES THAT THE TAX EFFECTS FROM AN UNCERTAIN TAX POSITION CAN BE RECOGNIZED IN THE FINANCIAL STATEMENTS ONLY IF THE POSITION IS MORE LIKELY THAT NOT TO BE SUSTAINED, IF THE POSITION WERE TO BE CHALLENGED BY A TAXING AUTHORITY. THE STANDARD ALSO PROVIDES GUIDANCE ON MEASUREMENT, CLASSIFICATION, INTEREST AND PENALTIES, AND DISCLOSURE. THE SOCIETY HAS PROCESSES PRESENTLY IN PLACE TO ENSURE THE MAINTENANCE OF ITS TAX-EXEMPT STATUS: TO IDENTIFY AND REPORT UNRELATED INCOME; TO DETERMINE ITS FILING AND TAX OBLIGATIONS IN JURISDICTIONS FOR WHICH IT HAS NEXUS: AND, TO IDENTIFY AND EVALUATE OTHER MATTERS THAT MAY BE CONSIDERED TAX POSITIONS. THE SOCIETY HAS DETERMINED THAT THERE ARE NO MATERIAL UNCERTAIN TAX POSITIONS THAT REQUIRE RECOGNITION OR DISCLOSURE IN THE CONSOLIDATED FINANCIALS STATEMENTS. IN ADDITION, THE SOCIETY HAS NOT RECORDED A PROVISION FOR INCOME TAXES AS IT HAS NO MATERIAL TAX LIABILITY FROM UNRELATED BUSINESS INCOME ACTIVITIES. INCOME AMOUNTS INCLUDED IN FINANCIALS - OTHER SCHEDULE D, PART XI, LINE 2D Other non-operating income $11,543 Change in fair value of beneficial interest in trust $64,079 Change in value of split-interest agreements $195,545 ---------- Total $271,167 true East Asia and the Pacific 4 Grantmaking 293421 Europe (Including Iceland and Greenland) 12 Grantmaking 1791458 Middle East and North Africa 2 Grantmaking 109366 North America 3 Grantmaking 590202 21 21 2784447 2784447 Europe (Including Iceland and Greenland) Research 120109 WIRE 0 East Asia and the Pacific Research 83521 WIRE 0 Europe (Including Iceland and Greenland) Research 107419 WIRE 0 Middle East and North Africa Research 78116 WIRE 0 East Asia and the Pacific Research 49833 WIRE 0 Europe (Including Iceland and Greenland) Research 669604 WIRE 0 Europe (Including Iceland and Greenland) Research 33476 WIRE 0 Middle East and North Africa Research 31250 WIRE 0 East Asia and the Pacific Research 125627 WIRE 0 North America Research 282232 WIRE 0 Europe (Including Iceland and Greenland) Research 50803 WIRE 0 Europe (Including Iceland and Greenland) Research 104039 WIRE 0 Europe (Including Iceland and Greenland) Research 50544 WIRE 0 Europe (Including Iceland and Greenland) Research 162351 WIRE 0 Europe (Including Iceland and Greenland) Research 115417 WIRE 0 North America Research 218328 WIRE 0 Europe (Including Iceland and Greenland) Research 98733 WIRE 0 Europe (Including Iceland and Greenland) Research 81532 WIRE 0 North America Research 89642 WIRE 0 East Asia and the Pacific Research 34440 WIRE 0 Europe (Including Iceland and Greenland) Fast Forward 197431 WIRE 0 21 false false false false false false PROCEDURES FOR MONITORING THE USE OF GRANT FUNDS SCHEDULE F, PART I, LINE 2 THE SOCIETY HAS INDEPENDENT RESEARCH ADVISORY COMMITTEES THAT EVALUATE ALL GRANT APPLICATIONS AND RECOMMEND GRANTS TO BE FUNDED BY THE SOCIETY BASED UPON THE QUALIFICATIONS OF THE INSTITUTION AND RESEARCHER(S), AND THE RESEARCH PROJECT'S SCIENTIFIC MERIT AND POTENTIAL APPLICABILITY TO MS. ONCE A GRANT HAS BEEN APPROVED, GRANTEES ARE REQUIRED TO SUBMIT PROGRESS REPORTS ON A QUARTERLY BASIS BEFORE ADDITIONAL FUNDING IS AUTHORIZED. X X X X X X X true MERKLE PO BOX 64897 BALTIMORE MD 21264 DONOR DATA false 8932845 2185128 6747717 CUSTOM BENEFIT AUCTIONS 2330 DULLES STATION BLVD 2110 HERNDON VA 20171 AUCTIONEER false 120145 4750 115395 IMPACT AUCTIONS 1717 SUTTER CREED DRIVE WAXHAW NC 28173 AUCTIONEER false 67419 2500 64919 CROWNOVER ENTERPRISES LLC 1194 BERKELEY RD AVONDALE ESTATES GA 30002 AUCTIONEER false 179542 4500 175042 9299951 2196878 7103073 AL AK AZ AR CA CO CT DE FL GA HI ID IL IN IA KS KY LA ME MD MA MI MN MS MO MT NE NV NH NJ NM NY NC ND OH OK OR PA RI SC SD TN TX UT VT VA WA WV WI WY Bike MS (36) 35786208 31766290 4019918 1032456 345583 498480 73382 2070017 Walk MS (353) 25290318 23872917 1417401 697596 124059 121510 13726 460510 39 14573829 12479203 2094626 58388 177310 640890 197656 1020382 75650355 68118410 7531945 1788440 646952 1260880 284764 3550909 7531945 Professional Fundraisers SCHEDULE G, PART I, LINE 2B THE SOCIETY USED MERKLE FOR THE MAJORITY OF ITS DIRECT MAIL CAMPAIGNS IN FY2020. THESE CAMPAIGNS COLLECTIVELY RAISED $8,932,845 IN REVENUE FOR FY2020. ADDITIONALLY, CROWNOVER ENTERPRISES, LLC, CUSTOM BENEFIT AUCTIONS AND IMPACT AUCTIONS ASSIST THE SOCIETY IN ACQUIRING MERCHANDISE TO BE AUCTIONED. COLLECTIVELY, THEY RAISED $367,105 IN REVENUE FOR FY2020. Fundraising Events Schedule G, Part II BIKE MS BIKE MS IS THE LARGEST FUNDRAISING BIKE SERIES IN THE WORLD. WITH BIKE MS RIDES ACROSS THE COUNTRY, ANYONE, ANYWHERE, CAN FUEL PROGRESS. DURING FY2020, 4,700 TEAMS AND MORE THAN 45,000 CYCLISTS CHOSE BIKE MS DURING THE 36 VIRTUAL AND IN-PERSON BIKE EVENTS HELD. WALK MS OVER 81,000 PEOPLE PARTICIPATE IN WALK MS EVENTS IN FY2020. WALK MS IS THE PERFECT PLACE TO CONNECT TO THE SERVICES AND SUPPORT OFFERRED BY THE NATIONAL MS SOCIETY. THERE WERE 353 VIRTUAL AND IN-PERSON WALK EVENTS HELD DURING FY2020. true Accelerated Cure Project 460 Totten Pond Road Waltham MA 02452 043555864 501(C)(3) 338195 0 Research Albert Einstein College of Medicine 1300 Morris Park Avenue Bronx NY 10461 472209056 501(C)(3) 90129 0 Research Baylor College of Medicine One Baylor Plaza Rm 600D Houston TX 77030 741613878 501(C)(3) 99504 0 Research Benaroya Research Institute 1201 9th Avenue Seattle WA 98101 910653422 501(C)(3) 165939 0 Research Berry College Inc 2277 Martha Berry Hwy NW Mt Berry GA 30149 580566133 501(C)(3) 54996 0 Research Beth Israel Deaconess Medical Center 330 Brookline Ave Boston MA 02215 042103881 501(C)(3) 75724 0 Research Boston Children's Hospital 300 Longwood Ave Boston MA 02115 042774441 501(C)(3) 51990 0 Research Brentwood Biomedical Research Institute 11301 Wilshire Blvd Los Angeles CA 90073 954183712 501(C)(3) 70215 0 Research Brigham & Women's Hospital 60 FENWOOD ROAD Boston MA 02115 042312909 501(C)(3) 1319578 0 Research Brown University Controllers off box J Providence RI 02912 050258809 501(C)(3) 20000 0 Research Case Western Reserve University 10900 Euclid Avenue Cleveland OH 44106 341018992 501(C)(3) 206048 0 Research Children's Hospital of Philadelphia 3401 Civic Cntr Blvd Philadelphia PA 19104 231352166 501(C)(3) 225118 0 Research Cleveland Clinic Foundation 9500 Euclid Avenue Cleveland OH 44195 912153073 501(C)(3) 1020723 0 Research Colorado State University 555 South Howes Fort Collins CO 80523 846000545 GOV. 34490 0 Research Columbia University 615 W 131st St 3rd Fl New York NY 10027 135598093 501(C)(3) 348013 0 Research Duke University PO box 602651 Durham NC 27710 560532129 501(C)(3) 205711 0 Research Emory University PO Box 935084 Atlanta GA 31193 580566256 501(C)(3) 55000 0 Research Georgetown University 37th and O Street NW Washington DC 20057 530196603 501(C)(3) 140863 0 Research Georgia State University Research FDN Inc PO Box 4030 Atlanta GA 30302 581845423 GOV. 54483 0 Research Gryphon Scientific 6930 Carroll Ave Takoma Park MD 20912 202858377 501(C)(3) 201609 0 Research Henry Ford Health System 2799 West Grand Boulevard Detroit MI 48202 381357020 501(C)(3) 180789 0 Research Henry M Jackson Foundation 6720-A Rockledge Dr Bethesda MD 20817 521317896 501(C)(3) 125402 0 Research Hugo W Moser Research Institute at Kennedy Kriege 707 North Broadway Baltimore MD 21205 521524967 501(C)(3) 55000 0 Research Icahn School of Medicine at Mount Sinai One Gustave L Levy Pl New York NY 10029 136171197 501(C)(3) 352681 0 Research Johns Hopkins University 1101 E 33rd St Baltimore MD 21218 520595110 501(C)(3) 1331934 0 Research Kent State University 800 East Summit St Kent OH 44242 316402079 GOV. 99815 0 Research Kessler Foundation Research Center 120 Eagle Rock Ave East Hanover NJ 07936 311562134 501(C)(3) 383422 0 Research Massachusetts General Hospital 55 Fruit St Boston MA 02114 041564655 501(C)(3) 643458 0 Research Mayo Clinic Rochester PO box 1658 Minneapolis MN 55480 416011702 501(C)(3) 458897 0 Research Medical University of South Carolina 19 Hagood Ave 505 Charleston SC 29425 576000722 501(C)(3) 55000 0 Research Montclair State University 1 Normal Ave Montclair NJ 07043 222912682 GOV. 200783 0 Research NAT'L Cancer Inst NAT'L Inst of Health 9000 Rockville Pike Bethesda MD 20892 520858115 501(C)(3) 89063 0 Research NATIONAL INSTITUTE OF NEUROLOGICAL DISORDER 9000 Rockville Pike Bethesda MD 20892 520858115 501(C)(3) 94338 0 Research National Institutes of Health 9000 Rockville Pike Bethesda MD 20892 521986675 501(C)(3) 23842 0 Research NAT'L Inst of HealthNAT'L Inst of Neurological Di 9000 Rockville Pike Bethesda MD 20892 520858115 501(C)(3) 90645 0 Research New York University 550 First Avenue New York NY 10016 135562308 501(C)(3) 308511 0 Research New York University School of Medicine 545 First Avenue New York NY 10016 135562308 501(C)(3) 15263 0 Research Northwestern University 633 Clark Street Evanston IL 60208 362167817 501(C)(3) 101781 0 Research Oregon Health & Science University 2525 SW 3rd Ave Ste 245 Portland OR 97201 931176109 501(C)(3) 1091408 0 Research Oregon State University A312 KERR ADMIN Corvallis OR 97331 611730890 GOV. 55156 0 Research REGENTS UNIVERSITY OF CALIFNORNIA LA 10889 Wilshire Blvd Los Angeles CA 90095 956006143 GOV. 353757 0 Research Research Foundation of CUNY-ASRC 230 W 41st St 7th Fl New York NY 10036 131988190 501(C)(3) 31891 0 Research Rocky Mountain MS Center Tissue Bank 8845 Wagner Street Westminster CO 80031 840795455 501(C)(3) 386504 0 Research Rutgers The State University of New Jersey 33 knightsbridge Road Piscataway NJ 08854 462354111 GOV. 655424 0 Research Saint Louis University 3545 Lindell Boulevard St Louis MO 63103 430654872 501(C)(3) 238278 0 Research Seattle Institute for Biomedical and Clinical Rese 1660 S CLB Way S-151F Seattle WA 98108 911452438 501(C)(3) 55000 0 Research Shepherd Center 2020 Peachtree Rd NW Atlanta GA 30309 510141601 501(C)(3) 112500 0 Research Southern California Permanente Medical 100 S Los Robles Ave Pasadena CA 91101 951750445 501(C)(3) 17526 0 Research St Jude Children's Research Hospital 262 Danny Thomas Pl Memphis TN 38105 620646012 501(C)(3) 110000 0 Research Stanford University 3145 Porter Drive Palo Alto CA 94304 941156365 501(C)(3) 492511 0 Research State University of New York at Stony Brook 100 Nicolls Rd Stony Brook NY 11794 141368361 GOV. 97046 0 Research Texas A&M AgriLife Research 400 Harvey Mitchell Pkwy Clg Stn TX 77845 749000541 GOV. 131416 0 Research The Curators of the University of Missouri 1 University Boulevard St Louis MO 63121 436003859 GOV. 203382 0 Research The J David Gladstone Institutes 1650 Owens Street San Francisco CA 94158 237203666 501(C)(3) 59027 0 Research The State University of New York at Buffalo 12 Capen Hall Buffalo NY 14260 161514621 GOV. 370981 0 Research The University of Iowa 105 Jessup Hall Iowa City IA 52242 426004813 501(C)(3) 106037 0 Research The University of Texas at San Antonio One UTSA Circle San Antonio TX 78249 741717115 GOV. 55391 0 Research Thomas Jefferson University 1020 Walnut Street Philadelphia PA 19107 231352651 501(C)(3) 296448 0 Research Tisch MS Research Center 521 W 57th St 4th Fl New York NY 10019 251922851 501(C)(3) 250000 0 Research University of Alabama at Birmingham 701 20th ST S-AB 921 Birmingham AL 35294 636005396 GOV. 547671 0 Research University of California San Diego 9500 Gilman Dr La Jolla CA 92093 956006144 GOV. 311361 0 Research University of California Berkeley 2227 Piedmont Avenue Berkeley CA 94720 946090626 GOV. 117744 0 Research University of California Davis 1850 Research Park Drive Davis CA 95618 946036494 GOV. 165391 0 Research University of California Riverside 900 University Ave Riverside CA 92521 956006142 GOV. 158830 0 Research University of California San Francisco 1855 Folsom Street San Francisco CA 94143 946036493 GOV. 1969292 0 Research University of Chicago 5801 South Ellis Avenue Chicago IL 60637 362177139 GOV. 239614 0 Research University of Colorado Denver 1800 Grant St Ste 500 Denver CO 80203 846000555 GOV. 388486 0 Research University of Connecticut 343 Mansfield RD Storrs Mansfield CT 06269 060772160 GOV. 101677 0 Research University of Connecticut Health Center 263 Farmington Avenue CB 8501 Farmington CT 06030 521725543 GOV. 398825 0 Research University of Florida PO box 113201 Gainesville FL 32611 596002052 GOV. 54313 0 Research University of Illinois at Chicago 800 S Marshfld Ave 511MB Chicago IL 60612 376000511 GOV. 152862 0 Research University of Illinois at Urbana-Champaign 1200 West Harrison St Urbana IL 61801 376000511 GOV. 642802 0 Research University of Maryland Baltimore 4100 Chesapeake Bldg College Park MD 20742 526002033 GOV. 55000 0 Research University of Massachusetts Medical School 55 N Lake Ave Worcester MA 01655 043167352 GOV. 77698 0 Research University of Michigan 5082 Wolverine Tower Ann Arbor MI 48109 386006309 GOV. 81711 0 Research University of North Carolina at Chapel Hill 153A Cntry Clb Rd Chapel Hill NC 27514 566001393 GOV. 488167 0 Research University of Pennsylvania 3451 Walnut Street Philadelphia PA 19104 231352685 GOV. 259112 0 Research University of Southern California University Gardens Los Angeles CA 90089 951642394 GOV. 345919 0 Research University of Utah 201S Prsdnts Cir Salt Lake City UT 84112 876000525 GOV. 1553513 0 Research University of Vermont 85 S Prospect St Burlington VT 05405 030179440 GOV. 32269 0 Research University of Virginia PO Box 400195 Charlottesville VA 22904 546001796 GOV. 61160 0 Research University of Washington 4300 Roosevelt Way NE Seattle WA 98195 916001537 GOV. 771312 0 Research Vanderbilt University 2301 Vanderbilt Plc Nashville TN 37240 620476822 501(C)(3) 53689 0 Research Vanderbilt University Medical Center 1161 21st Ave Ste Nashville TN 37232 352528741 501(C)(3) 217981 0 Research Versiti Wisconsin Inc 638 N 18th Street Milwaukee WI 53233 390807235 501(C)(3) 225777 0 Research Virginia Commonwealth University PO Box 843035 Richmond VA 23284 546001758 GOV. 246929 0 Research Washington University School of Medicine 660 Euclid Ave CB8501 St Louis MO 63110 430653611 GOV. 1302326 0 Research Weill Cornell Medical College 1300 York Avenue New York NY 10065 131623978 501(C)(3) 294175 0 Research Westat 1600 Research Boulevard Rockville MD 20850 840529566 501(C)(3) 10069 0 Research Yale University 2 Whitney Ave 6th Fl New Haven CT 06510 060646973 501(C)(3) 393333 0 Research Brainstrom Cell Therapeutics Inc 1325 Ave of the Amer New York NY 10019 207273918 N/A 321965 0 RESEARCH Cashel Neural Inc 10000 Cedar Avenue Cleveland OH 44106 824625105 501(C)(3) 174154 0 RESEARCH Clene Nanomedicine Inc 3165 E MillrOck Dr Salt Lake City UT 84121 320446164 N/A 322270 0 RESEARCH Longevity Biotech Inc 3001 Market St Philadelphia PA 19104 272351016 N/A 10310 0 RESEARCH TG Therapeutics Inc 2 Gansevoort St 9th fl New York NY 10014 363898269 501(C)(3) 12723 0 RESEARCH Therini Bio Inc 1080 Marsh Rd Menlo Park CA 94025 814579978 N/A 61940 0 RESEARCH University of California Riverside 900 University Ave Riverside CA 92521 956006142 GOV. 130706 0 RESEARCH Brigham and Women's Hospital 75 Francis Street Boston MA 02115 042312909 501(C)(3) 18750 0 Clinical Children's Hospital of Philadelphia 3401 Civic Ctr Bldg Philadelphia PA 19104 231352166 501(C)(3) 95500 0 Clinical Cleveland Clinic Foundation 9500 Euclid Avenue Cleveland OH 44195 912153073 501(C)(3) 177300 0 Clinical Icahn School of Medicine at Mount Sinai 1 Gustave L Levy Place New York NY 10029 136171197 501(C)(3) 112250 0 Clinical Johns Hopkins University 1101E 33rd St Ste D200 Baltimore MD 21218 520595110 501(C)(3) 112111 0 Clinical New York University 550 First Avenue New York NY 10016 135562308 501(C)(3) 75000 0 Clinical Oregon Health & Science University 2525 SW 3rd Ave Ste 245 Portland OR 97201 931176109 501(C)(3) 93500 0 Clinical The Uni of Texas Southwestern Medical Ctr 5323 Harry Hines Blvd Dallas TX 75390 756002868 501(C)(3) 109570 0 Clinical University of Alabama at Birmingham 701 20th St S-AB 921 Birmingham AL 35294 636005396 GOV. 18750 0 Clinical University of California San Diego 9500 Gilman Dr La Jolla CA 92093 956006144 GOV. 18750 0 Clinical University of California San Francisco 1855 Folsom Street San Francisco CA 94143 946036493 GOV. 29219 0 Clinical University of Colorado Denver 1800 Grant St Ste 500 Denver CO 80203 846000555 GOV. 56250 0 Clinical University of Massachusetts Medical School 55 N Lake Ave Worcester MA 01655 043167352 GOV. 90750 0 Clinical University of Rochester Medical Center 518 Hylan Building Rochester NY 14627 160743209 501(C)(3) 93500 0 Clinical University of Southern California University Gardens Los Angeles CA 90089 951642394 GOV. 99063 0 Clinical University of Texas at Austin 110 Inner Campus Dr Austin TX 78712 746000203 GOV. 75000 0 Clinical University of Washington 4300 Roosevelt Way NE Seattle WA 98195 916001537 GOV. 107869 0 Clinical Vanderbilt University Medical Center 1161 21st Ave Nashville TN 37232 352528741 501(C)(3) 75000 0 Clinical Virginia Commonwealth University PO Box 843035 Richmond VA 23284 546001758 501(C)(3) 136448 0 Clinical 112 4 FINANCIAL ASSISTANCE 3438 2905802 PROCEDURES FOR MONITORING THE USE OF GRANT FUNDS SCHEDULE I, PART I, LINE 2 RESEARCH GRANTS THE SOCIETY UTILIZES VOLUNTEER COMMITTEES OF RENOWNED SCIENTISTS AND NEUROLOGISTS TO SELECT RESEARCH GRANTS FOR FUNDING IN THE UNITED STATES AND ABROAD. ALL GRANTEES ARE TO PROVIDE SCIENTIFIC AND FINANCIAL PROGRESS REPORTS ON A QUARTERLY BASIS WHICH ARE REVIEWED BY QUALIFIED STAFF. FINANCIAL ASSISTANCE GRANTS MS NAVIGATORS WORK WITH EACH INDIVIDUAL TO DEVELOP AN ASSISTANCE REQUEST THAT WOULD LEAD TO A CUSTOMIZED AND SUSTAINABLE SOLUTION. OTHER POTENTIAL RESOURCES ARE EXPLORED AND A DETERMINATION IS MADE WHETHER THE ASSISTANCE REQUEST MEETS THE CRITERIA ESTABLISHED IN THE SOCIETY'S FINANCIAL ASSISTANCE GUIDELINES. approved requests result in payments made directly to the vendor specified in the request. X X X X X false false false false false false false false false CYNTHIA ZAGIEBOYLO PRESIDENT & CEO 570915 0 0 0 0 0 11200 0 1715 0 583830 0 0 0 TAMI CAESAR CFO & COO 300378 0 0 0 0 0 11200 0 35626 0 347204 0 0 0 ERIC HILTY CHIEF LEGAL OFF.(THRU 11/6/20) 236833 0 0 0 0 0 9191 0 30081 0 276105 0 0 0 PAUL WEISS THRU 11220 CHIEF CRM, MKT & TECH OFFICER 343839 0 0 0 0 0 11200 0 31693 0 386732 0 0 0 TIM COETZEE CHIEF ADVOC, SVC & RSRCH OFFCR 335983 0 0 0 0 0 11200 0 38037 0 385220 0 0 0 JOHN SCOTT CHIEF DEV & COMM LEAD. OFFICER 345012 0 0 0 0 0 11200 0 16443 0 372655 0 0 0 LISA GOLDFARB CHIEF HR & VOL ENG OFFICER 312801 0 0 0 0 0 11200 0 2867 0 326868 0 0 0 BRUCE BEBO EVP, RESEARCH PROGRAMS 209849 0 0 0 0 0 18651 0 21227 0 249727 0 0 0 RON ZWERIN EVP, MARKETING 212028 0 0 0 0 0 0 0 32247 0 244275 0 0 0 ELIZABETH CRITES EVP, INDIV GIVING & CORP REL 208705 0 0 0 0 0 7754 0 4672 0 221131 0 0 0 REBECCA FEHLIG EVP, OPERATIONS 191466 0 0 0 0 0 6430 0 1814 0 199710 0 0 0 MAUREEN REEDER EVP, LEAD & ORG(THRU 01/25/19) 290484 0 0 0 0 0 2430 0 415 0 293329 0 0 0 JENNIFER LEE EVP, FUNDRAISING EVENTS 257154 0 0 0 0 0 10400 0 23813 0 291367 0 0 0 PHYLLIS ROBSHAM EVP, COMMUNITY LEADERSHIP 258254 0 0 0 0 0 10328 0 13988 0 282570 0 0 0 BARI TALENTE EVP, ADVOCACY 225666 0 0 0 0 0 6932 0 39830 0 272428 0 0 0 KAY JULIAN EVP, SERVICES (THRU 11/02/20) 241504 0 0 0 0 0 9760 0 16290 0 267554 0 0 0 GRAHAM MCREYNOLDS FMR AVP, GLOBAL INITIATIVES 101308 0 0 0 0 0 4101 0 19970 0 125379 0 0 0 SCHEDULE J, PART II, COMPENSATION The compensation information reported on part VII and Schedule J is based on the 2019 calendar year and predates the COVID pandemic that has greatly impacted the Societys operations. Salary reductions for highly compensated employees were implemented in 2020 as part of the COVID-19 Contingency Plan to reduce expenses while retaining employees and delivering on our mission. Those reductions will be reflected in next years filing. X 177 2289940 FMV false true false NUMBER OF CONTRIBUTIONS SCHEDULE M, PART I, LINE 9 THE ORGANIZATION IS REPORTING THE NUMBER OF NONCASH CONTRIBUTIONS RECEIVED, NOT THE NUMBER OF ITEMS CONTRIBUTED. COVID-19 IMPACT In early 2020, an outbreak of the novel strain of coronavirus ("COVID-19") EMERGED ON A GLOBAL SCALE. IN REACTION TO THE OUTBREAK, FEDERAL, state, and local governments issued mandates that disrupted businesses and resulted in an overall decline in economic activity. Despite the operating challenges it presented, the Society remained focused on delivering its core mission. The pandemic caused the Society to close offices across the country and shift its operations, events and community programs to a remote status, which remained in effect through the end of fiscal 2020 and into fiscal 2021. Donor-based revenues have been materially impacted, as in-person fundraising events moved to virtual events and connections with donors and people affected by MS turned to online formats. Overall, the impact was a reduction of 21% of total revenues for the year ended September 30, 2020, as compared to the prior year. An expense contingency plan was developed, INCLUDING COMPENSATION REDUCTIONS TO THOSE PAID OVER $100,000, and the Societys research and other operating expenses were reduced focusing on the least disruption to the mission until the effects of the pandemic lessen. PROGRAM SERVICE ACCOMPLISHMENTS OTHER PROGRAM SERVICES FORM 990, PART III, LINE 4D PROFESSIONAL EDUCATION AND TRAINING THE SOCIETY WANTS SCIENTISTS AND HEALTHCARE PROFESSIONALS TO BE AWARE OF AND TRAINED IN MS SO THAT THE VERY BEST EXPERTISE WORLDWIDE IS ENGAGED IN FINDING TREATMENTS AND SOLUTIONS FOR EVERYONE WITH MS. THIS INCLUDES ACTIVITIES AND PROGRAMS DESIGNED TO IMPROVE THE KNOWLEDGE, SKILLS, AND CRITICAL JUDGEMENT OF SCIENTISTS, PHYSICIANS AND OTHER HEALTHCARE PROFESSIONALS ENGAGED (DIRECTLY OR INDIRECTLY) IN PROVIDING SERVICES TO PEOPLE LIVING WITH MS BY KEEPING THEM ABREAST OF NEW DIAGNOSTIC TECHNIQUES AND THERAPIES - 5,743 HEALTHCARE PROVIDERS PARTICIPATED IN THESE PROGRAMS DURING 2020. OF THOSE WHO ATTENDED, 86% REPORTED INCREASED KNOWLEDGE ABOUT MS CARE. IN 2020, HEALTHCARE PROVIDERS MADE 8,711 REFERRALS TO THE SOCIETY. CLASSES OF MEMBERS OR STOCKHOLDERS FORM 990, PART VI, SECTION A, LINE 6 THE MEMBERS OF THE SOCIETY ARE COMPRISED OF THE MEMBERS OF THE 34 MARKETS WHO ARE NON-VOTING MEMBERS, AND THOSE MARKETS CHOOSE VOTING MEMBERS WHO COMPRISE THE DELEGATE ASSEMBLY. ELECTION OF MEMBERS AND THEIR RIGHTS FORM 990, PART VI, SECTION A, LINE 7A ALL MEMBERS OF THE BOARD OF DIRECTORS ARE ELECTED BY THE DELEGATE ASSEMBLY WHICH IS COMPRISED OF VOTING MEMBERS OF THE ORGANIZATION. EACH MARKET IS ALLOCATED A NUMBER OF VOTING MEMBERS BASED ON A FORMULA. VOTING MEMBERS ARE THE VOLUNTEER LEADERS OF THE MARKET AND THE NATIONAL BOARD OF DIRECTORS. DECISIONS SUBJECT TO APPROVAL OF MEMBERS FORM 990, PART VI, SECTION A, LINE 7B THE DELEGATE ASSEMBLY ELECTS THE GOVERNING BODY, APPROVES ANY BY-LAW CHANGES AND APPROVES THE SOCIETY'S STRATEGIC PLAN. ORGANIZATION'S PROCESS TO REVIEW FORM 990 FORM 990, PART VI, SECTION B, LINE 11B THE FORM 990 AND ACCOMPANYING SCHEDULES ARE PREPARED BY AN EXTERNAL INDEPENDENT ACCOUNTING FIRM IN CONJUNCTION WITH MANAGEMENT. IT IS THEN PROVIDED TO THE AUDIT COMMITTEE MEMBERS FOR REVIEW, COMMENTS, CORRECTIONS, AND EDITS. THE REVIEW COMMENTS OF THE AUDIT COMMITTEE ARE INCORPORATED INTO THE FORM 990 BY THE CFO. A MEETING OF THE AUDIT COMMITTEE IS HELD TO APPROVE THE REVISED FORM 990, AND TO APPROVE DISTRIBUTION TO THE ENTIRE SOCIETY BOARD OF DIRECTORS. THE SOCIETY BOARD OF DIRECTORS IS GIVEN A PERIOD OF TIME TO REVIEW AND COMMENT ON THE FORM 990 BEFORE THE RETURN IS FILED WITH THE INTERNAL REVENUE SERVICE. ENFORCEMENT OF CONFLICTS POLICY FORM 990, PART VI, SECTION B, LINE 12C ALL STAFF AND MEMBERS OF THE NATIONAL BOARD OF DIRECTORS AND VOLUNTEERS SERVING ON KEY COMMITTEES MUST REVIEW THE CONFLICT OF INTEREST POLICY & MAKE ANY APPROPRIATE DISCLOSURES. IF AN INDIVIDUAL DISCLOSES AN ACTUAL OR POTENTIAL CONFLICT, THE LEGAL TEAM REVIEWS THE DISCLOSURE AND DRAFTS A CONFLICT RESOLUTION REPORT TO ADDRESS THE ACTUAL OR POTENTIAL CONFLICT. THE RESOLUTION REPORT IS PRESENTED TO THE AUDIT COMMITTEE AND THE AUDIT COMMITTEE EDITS AND ULTIMATELY APPROVES A RESOLUTION REPORT FOR EACH OF THE DISCLOSED CONFLICTS. THE RESOLUTION REPORT ENSURES THAT THE INDIVIDUAL DOES NOT PARTICIPATE IN ANY DISCUSSIONS OR VOTES RELATED TO THE CONFLICT. THE INDIVIDUAL WHO DISCLOSED THE CONFLICT IS PROVIDED A COPY OF THE RESOLUTION REPORT AND COMPLIES WITH IT. COMPENSATION PROCESS FORM 990, PART VI, SECTION B, LINE 15A THE COMPENSATION COMMITTEE IS COMPRISED OF AT LEAST THREE (3) INDEPENDENT BOARD MEMBERS THAT DETERMINE THE COMPENSATION OF THE PRESIDENT AND CEO, OFFICERS AND OTHER KEY EMPLOYEES. THE COMMITTEE IS PROVIDED WITH COMPARABLE SALARY INFORMATION AND DATA FOR ALL POSITIONS AT OTHER VOLUNTARY HEALTHCARE AGENCIES OF SIMILAR SIZE AND NATIONAL INFLUENCE. THE PRESIDENT AND CEO'S PERFORMANCE IS EVALUATED ON AN ANNUAL BASIS BY THE MEMBERS OF THE COMPENSATION COMMITTEE. THE PRESIDENT AND CEO COMPENSATION IS reviewed with THE BOARD DURING EXECUTIVE SESSION. THE PRESIDENT AND CEO OR HER DESIGNEE CONDUCTS PERFORMANCE EVALUATIONS FOR OFFICERS AND OTHER KEY EMPLOYEES. THE OUTCOME OF THESE EVALUATIONS IS SHARED WITH THE COMPENSATION COMMITTEE TO PROVIDE INFORMATION ON THEIR DECISIONS ABOUT COMPENSATION AND IS REVIEWED WITH THE BOARD DURING EXECUTIVE SESSION. GOVERNING DOCUMENTS DISCLOSURE EXPLANATION FORM 990, PART VI, SECTION C, LINE 19 THE SOCIETYS IRS FORM 990, IRS FORM 990-T AND AUDITED FINANCIAL STATEMENTS ARE AVAILABLE AT WWW.NATIONALMSSOCIETY.ORG, AND ON THE CHARITY NAVIGATOR WEBSITE. THE SOCIETY'S GOVERNING DOCUMENTS, RECORD RETENTION AND CONFLICT OF INTEREST POLICY ARE AVAILABLE UPON REQUEST. OTHER CHANGES IN NET ASSETS EXPLANATION FORM 990, PART XI, LINE 9 Other non-operating income $ 11,543 Change in fair value of beneficial interest in trust $ 64,079 Change in value of split-interest agreements $ 195,545 ------------ Total $ 271,167 FAST FORWARD LLC 733 THIRD AVENUE NEW YORK NY 100173822 261933619 RESEARCH DE 590897 1550427 NMSS DISREGARDED ENTITIES SCHEDULE R, PART I, FAST FORWARD LLC ("FAST FORWARD"), A CONSOLIDATED NOT-FOR-PROFIT AFFILIATE OF THE SOCIETY, DERIVES ITS TAX EXEMPTION FROM THE SOCIETY AND IS TREATED AS A "DISREGARDED ENTITY" FOR TAX PURPOSES. FAST FORWARD PARTNERS WITH SELECTED BIOTECHNOLOGY COMPANIES AND ACADEMIC INSTITUTIONS ENGAGED IN RESEARCH AND DEVELOPMENT PROJECTS AIMED AT IDENTIFYING AND DEVELOPING THERAPIES AND/OR DIAGNOSTICS TO IMPROVE THE TREATMENT OF MS.